Lupoid sclerosis: What is the role of antiphospholipid antibodies?

Journal of Clinical Rheumatology

Volumn 13, Issue 2, 2007, Pages 85-86

  Lima, Isabella ^a   Melo, Ailton ^b   Brandi, Ivar Viana ^c   Costa, Olívia ^d   Santiago, Mittermayer ^a,e  

^a HOSPITAL SANTA IZABEL   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Setor de Patologia Genetica   (Brazil)

^d Maternidade Climerio de Oliveira   (Brazil)

^e ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

Author keywords

Antiphospholipid syndrome; Lupoid sclerosis; Lupus; Multiple sclerosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; CARDIOLIPIN ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; RITUXIMAB; WARFARIN;

ADULT; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CAUCASIAN; CHILL; CLINICAL FEATURE; COMORBIDITY; DEEP VEIN THROMBOSIS; DEMYELINATION; DISEASE COURSE; DRUG FEVER; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; LIVEDO RETICULARIS; LUPOID SCLEROSIS; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUADRIPLEGIA; SCLEROSIS; TONGUE EDEMA; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS;

EID: 34247135855     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000260637.95695.40     Document Type: Article

References (13)

1. Hughes GRV. Migraine, memory loss, and "multiple sclerosis." Neurological features of the antiphospholipids (Hughe's) syndrome. Postgrad Med J. 2003;79:81-83.
2. Chapman J, Rand JH, Brey RL, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus. 2003;12:514-517.
3. Hughes GRV. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J. 1983;287:1088-1089.
4. Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol. 1987;44:876-883.
5. Garriga JS, Montalban X. APS and the brain. Lupus. 2003;12:877-882.
6. Ijdo JW, Conti-Kelly AM, Greco P, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus. 1999;8:109-115.
7. Karussis D, Leker RR, Ashkenazi A. Abramsky. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44:629-634.
8. Ferreira S, D'Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology. 2005;44:434-442.
9. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine. 2000;79:57-68.
10. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004;89:ECR34.
11. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503.
12. Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology. 2004;28:63(12 Suppl 6):S47-S54.
13. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells inpatients with primary progressive MS. Arch Neurol. 2005;62:258-264.